Y 32885

1.	Amano, Yusaku: 2 articles (10/2003 - 01/2003)
2.	Nakajima, Masahide: 2 articles (10/2003 - 01/2003)
3.	Egi, Yasuhiro: 2 articles (10/2003 - 01/2003)
4.	Kondo, Takao: 2 articles (10/2003 - 01/2003)
5.	Hayashi, Kazutaka: 2 articles (10/2003 - 01/2003)
6.	Goto, Nobuharu: 2 articles (10/2003 - 01/2003)
7.	Katayama, Ken-ichi: 2 articles (10/2003 - 01/2003)
8.	Uehata, Masayoshi: 2 articles (10/2003 - 01/2003)
9.	Kataoka, Hirotoshi: 1 article (10/2003)
10.	Ohtsuki, Makio: 1 article (10/2003)

Related Diseases

1.	Neoplasms (Cancer) 01/17/2003 - "We conclude that Wf-536 has tumor anti-metastatic activity which may depend on inhibition of tumor motility and angiogenesis" 10/01/2003 - "CONCLUSION: The results suggest that Wf-536 is a potentially valuable drug for preventing tumor metastasis both in monotherapy and in combination with an antineoplastic drug." 10/01/2003 - "In vivo, Wf-536 administration suppressed tumor colony formation on the lung surface in a dose-dependent manner (0.3-3 mg/kg per day), with a metastasis inhibition rate of 95% at 3 mg/kg per day" 01/17/2003 - "Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions." 10/01/2003 - "In experimental metastasis of B16F10 melanoma, oral administration of Wf-536 significantly decreased tumor colony formation in the lung, with an inhibition rate of 41% at 3 mg/kg per day" Get all the results and reference details, order at left...
2.	Neoplasm Metastasis (Metastasis) 07/01/2003 - "5. These results suggest that Wf-536 suppresses tumour metastasis by both enhancing the barrier function of host cell layers and inhibiting tumour cell motility at the stage of host tissue penetration by metastatic tumour cells." 07/01/2003 - "To clarify the mechanism of Wf-536 in inhibition of tumour metastasis, we analysed the effect of Wf-536 on the transition of tumour cells through the host cell layer and the basement membrane in in vitro systems" 10/01/2003 - "CONCLUSION: The results suggest that Wf-536 is a potentially valuable drug for preventing tumor metastasis both in monotherapy and in combination with an antineoplastic drug." 10/01/2003 - "In vivo, Wf-536 administration suppressed tumor colony formation on the lung surface in a dose-dependent manner (0.3-3 mg/kg per day), with a metastasis inhibition rate of 95% at 3 mg/kg per day" 10/01/2003 - "Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma." Get all the results and reference details, order at left...
3.	Lewis Lung Carcinoma 01/17/2003 - "Wf-536 (0.3-3 mg/kg/day) was found to inhibit Lewis lung carcinoma (LLC) metastasis and LLC-induced angiogenesis in orally treated mice; in vitro, it inhibited both invasion and migration by LLC cells and invasion, migration, and formation of capillary-like tubes on Matrigel by endothelial cells, without cytotoxicity or anti-proliferative action in either cell type" Get all the results and reference details, order at left...
4.	Experimental Melanoma 10/01/2003 - "Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma." Get all the results and reference details, order at left...
5.	Melanoma (Melanoma, Malignant) 10/01/2003 - "In experimental metastasis of B16F10 melanoma, oral administration of Wf-536 significantly decreased tumor colony formation in the lung, with an inhibition rate of 41% at 3 mg/kg per day" 10/01/2003 - "METHODS: The following were evaluated: the anti-invasive effect of Wf-536 against the motility of mouse B16BL6 melanoma cells through a culture insert layered with reconstituted basement membrane (Matrigel); the cytotoxic effect of Wf-536 in the same cell line; the antimetastatic effect of Wf-536, administered by osmotic pump, on spontaneous pulmonary metastasis following subcutaneous injection of B16BL6 melanoma in mice; and the inhibitory effect of orally administered Wf-536, alone or in combination with the antineoplastic drug paclitaxel, on pulmonary metastasis of intravenously injected B16F10 melanoma in mice" Get all the results and reference details, order at left...
7 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	benzamide
2.	Paclitaxel (Taxol)
3.	matrigel
4.	marimastat
4 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>